RxSight reported a 4% decrease in total revenue to $33.6 million in Q2 2025 compared to the previous year, primarily due to a significant 50% decline in Light Delivery Device (LDD) revenue, despite a 13% increase in Light Adjustable Lens (LAL) revenue. The company experienced a net loss of $(11.8) million, or $(0.29) per share, widening from a net loss of $(6.1) million in Q2 2024. Gross profit improved to $25.2 million, or 74.9% of revenue, driven by a favorable shift towards LAL sales.
Total revenue for Q2 2025 was $33.6 million, a 4% decrease from $34.9 million in Q2 2024.
Light Adjustable Lens (LAL) sales increased by 13%, while Light Delivery Device (LDD) sales decreased by 50% compared to the second quarter of 2024.
The company reported a net loss of $(11.8) million, or $(0.29) per basic and diluted share, compared to a net loss of $(6.1) million, or $(0.16) per share, in Q2 2024.
Gross profit increased to $25.2 million (74.9% of revenue) in Q2 2025, up from $24.3 million (69.5% of revenue) in Q2 2024, driven by a favorable product mix.
RxSight reaffirmed its 2025 full-year guidance for revenue, gross margin, and operating expenses, anticipating a revenue decrease of 7% to 14% compared to 2024, an increase in gross margin, and an increase in operating expenses.
Analyze how earnings announcements historically affect stock price performance